var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('3/27 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | \n'); } if (allow) { document.write('
3/20 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 | \n'); } if (allow) { document.write('
3/14 - 8:53 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences to Present at the 36th Annual Roth Conference | \n'); } if (allow) { document.write('
3/4 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer | \n'); } if (allow) { document.write('
2/7 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | \n'); } if (allow) { document.write('
1/30 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study | \n'); } if (allow) { document.write('
1/25 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million | \n'); } if (allow) { document.write('
1/22 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom\'s Macroglobulinemia Patient | \n'); } if (allow) { document.write('
1/16 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data | \n'); } if (allow) { document.write('
1/12 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results | \n'); } if (allow) { document.write('
1/11 - 6:40 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom\'s Macroglobulinemia in the Community Setting | \n'); } if (allow) { document.write('
1/8 - 6:30 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom\'s Macroglobulinemia | \n'); } if (allow) { document.write('
1/3 - 8:32 AM \; \; | \n'); } if (allow) { document.write('Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |